嵌合染色体改变与多基因风险评分的交互作用与肺癌风险:基于芯片的病例对照关联与前瞻性队列研究
研究利用南京肺癌队列(NJLCC)病例对照与英国生物银行(UKB)前瞻性队列,分析血液DNA嵌合染色体改变(mCA)与肺癌风险的关系及其与多基因风险评分(PRS)的交互作用。结果显示mCA携带者肺癌风险升高,且与PRS存在显著相乘和相加交互,提示mCA或可与PRS联合用于个体化风险分层。
要点
- mCA携带者肺癌风险升高:NJLCC的OR 1.81,UKB的HR 1.40。
- mCA细胞分数≥10%者风险更高:NJLCC的OR 1.61 vs 1.03。
- mCA与PRS存在相乘交互:NJLCC交互P=0.030,UKB P=0.043。
核心结论
- mCA可作为肺癌风险的新内源性指标,并可能与PRS联合用于优化个体化风险分层。
研究设计与样本
- NJLCC研究纳入肺癌患者10248例与无癌对照9298例,采用Global Screening Array基因分型并以MoChA流程检测mCA。
- UKB前瞻性队列纳入450821人,其中肺癌2088例,通过国家癌症登记链接确定发病。
- NJLCC采用逻辑回归、UKB采用Cox比例风险模型评估mCA与肺癌风险的关联。
主要发现
- 与mCA缺失非携带者相比,携带者肺癌风险在NJLCC显著升高(OR 1.81,95%CI 1.43-2.28;P=6.69×10⁻⁷),在UKB亦升高(HR 1.40,95%CI 1.00-1.95;P=0.048)。
- NJLCC中mCA细胞分数≥10%者OR 1.61(95%CI 1.26-2.08),细胞分数<10%者OR 1.03(95%CI 0.83-1.26),异质性检验P=6.41×10⁻³。
- PRS与mCA缺失对肺癌风险存在显著相乘交互:NJLCC交互P=0.030,UKB P=0.043。
- NJLCC中,细胞分数≥10%的mCA缺失且高遗传风险者相比无mCA缺失且低遗传风险者,肺癌风险OR 6.40(95%CI 3.22-12.69);UKB中相应HR 3.75(95%CI 1.86-7.55)。
- 相加交互的相对超额风险:NJLCC为3.67(95%CI 0.49-6.85),UKB为2.15(95%CI 0.12-4.19)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mosaic chromosomal alterations (mCAs) detected from blood-derived DNA are large structural alterations of clonal haematopoietic origin and are associated with various diseases, such as haematological malignancies, infections, and solid cancers. We aimed to investigate whether mCAs contribute to the risk of lung cancer and modify the effect of polygenic risk score (PRS) on lung cancer risk prediction. METHODS: The blood-derived DNA of patients with lung cancer and cancer-free controls with Chinese ancestry from the Nanjing Lung Cancer Cohort (NJLCC) study were genotyped with a Global Screening Array, and mCAs were detected with the Mosaic Chromosomal Alterations (MoChA) pipeline. mCA call sets of individuals with European ancestry were obtained from the prospective cohort UK Biobank (UKB) study, including documented incident lung cancer. All patients with lung cancer from the NJLCC study (aged 15 years or older at diagnosis) were histopathologically confirmed as new lung cancer cases by at least two pathologists and were free of chemotherapy or radiotherapy before diagnosis. Participants with incident lung cancer (aged 37-73 years at assessment) diagnosed after recruitment to the UKB were identified through linkage to national cancer registries. Logistic regression and Cox proportional hazard models were applied to evaluate associations between mCAs and risk of lung cancer in the NJLCC (logistic regression) and UKB (Cox proportional hazard model) studies. FINDINGS: The NJLCC study included 10 248 individuals (6445 [62·89%] men and 3803 [37·11%] women; median age 60·0 years [IQR 53·0-66·0]) with lung cancer and 9298 individuals (5871 [63·14%] men and 3427 [36·86%] women; median age 60·0 years [52·0-65·0]) without lung cancer recruited from three sub-regions (north, central, and south) across China between April 15, 2003, and Aug 18, 2017. The UKB included 450 821 individuals recruited from 22 centres across the UK between March 13, 2006, and Nov 1, 2010, including 2088 individuals with lung cancer (1075 [51·48%] men and 1013 [48·52%] women; median age 63·0 years [IQR 59·0-66·0]), and 448 733 participants were free of lung cancer (204 713 [45·62%] men and 244 020 [54·38%] women; median age 58·0 years [IQR 50·0-63·0]). Compared with non-carriers of mosaic losses, carriers had a significantly increased risk of lung cancer in the NJLCC (odds ratio [OR] 1·81, 95% CI 1·43-2·28; p=6·69 × 10-7) and UKB (hazard ratio [HR] 1·40, 95% CI 1·00-1·95; p=0·048) studies. This increased risk was even higher in patients with expanded cell fractions of mCAs (ie, cell fractions ≥10% vs cell fractions <10%) in the NJLCC (OR 1·61 [95% CI 1·26-2·08] vs 1·03 [0·83-1·26]; p for heterogeneity test=6·41 × 10-3). A significant multiplicative interaction was observed between PRS and mosaic losses on the risk of lung cancer in both the NJLCC (interaction p value=0·030) and UKB (p=0·043). Compared with non-carriers of mosaic loss abnormalities with low genetic risk, participants with expanded mosaic losses (cell fractions ≥10%) and high genetic risk had around a six-times increased risk of lung cancer in the NJLCC study (OR 6·40 [95% CI 3·22-12·69]), and an almost four-times increased risk of lung cancer (HR 3·75 [95% CI 1·86-7·55]) in the UKB study. The additive interaction also contributed a 3·67 (95% CI 0·49-6·85) relative excess risk of developing lung cancer in the NJLCC study, and a 2·15 (0·12-4·19) relative excess risk in the UKB study. INTERPRETATION: mCAs act as a new endogenous indicator for the risk of lung cancer and might be jointly used with PRS to optimise personalised risk stratification for lung cancer. FUNDING: National Natural Science Foundation of China, Outstanding Youth Foundation of Jiangsu Province, Natural Science Foundation of Jiangsu Province, and Postdoctoral Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Qin N, Wang C, Chen C, et al. Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study. Lancet Oncol. 2022. PMID: 36265503. doi:10.1016/S1470-2045(22)00600-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。